194 related articles for article (PubMed ID: 24218996)
1. Clinical relevance of the interaction when switching non-nucleoside reverse transcriptase inhibitors in patients infected with HIV.
Dailly E; Allavena C; Deslandes G; Bouquie R; Jolliet P; Raffi F
Curr Clin Pharmacol; 2014; 9(4):399-403. PubMed ID: 24218996
[TBL] [Abstract][Full Text] [Related]
2. Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment.
Wang Y; De Clercq E; Li G
Expert Opin Drug Metab Toxicol; 2019 Oct; 15(10):813-829. PubMed ID: 31556749
[No Abstract] [Full Text] [Related]
3. Role of non-nucleoside reverse transcriptase inhibitors in treating HIV-infected children.
Penazzato M; Giaquinto C
Drugs; 2011 Nov; 71(16):2131-49. PubMed ID: 22035514
[TBL] [Abstract][Full Text] [Related]
4. Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing.
Melikian GL; Rhee SY; Varghese V; Porter D; White K; Taylor J; Towner W; Troia P; Burack J; Dejesus E; Robbins GK; Razzeca K; Kagan R; Liu TF; Fessel WJ; Israelski D; Shafer RW
J Antimicrob Chemother; 2014 Jan; 69(1):12-20. PubMed ID: 23934770
[TBL] [Abstract][Full Text] [Related]
5. [Role of etravirine in combination antiretroviral therapy].
Domingo P
Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():46-51. PubMed ID: 20116628
[TBL] [Abstract][Full Text] [Related]
6. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.
Delaugerre C; Rohban R; Simon A; Mouroux M; Tricot C; Agher R; Huraux JM; Katlama C; Calvez V
J Med Virol; 2001 Nov; 65(3):445-8. PubMed ID: 11596076
[TBL] [Abstract][Full Text] [Related]
7. Rilpivirine, a novel non-nucleoside reverse transcriptase inhibitor for the management of HIV-1 infection: a systematic review.
Schafer JJ; Short WR
Antivir Ther; 2012; 17(8):1495-502. PubMed ID: 22878339
[TBL] [Abstract][Full Text] [Related]
8. Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.
Bunupuradah T; Ananworanich J; Chetchotisakd P; Kantipong P; Jirajariyavej S; Sirivichayakul S; Munsakul W; Prasithsirikul W; Sungkanuparph S; Bowonwattanuwong C; Klinbuayaem V; Petoumenos K; Hirschel B; Bhakeecheep S; Ruxrungtham K
Antivir Ther; 2011; 16(7):1113-21. PubMed ID: 22024527
[TBL] [Abstract][Full Text] [Related]
9. Emerging mutations and associated factors in patients displaying treatment failure on an etravirine-containing regimen.
Marcelin AG; Descamps D; Tamalet C; Cottalorda J; Izopet J; Delaugerre C; Morand-Joubert L; Trabaud MA; Bettinger D; Rogez S; Ruffault A; Henquell C; Signori-Schmuck A; Bouvier-Alias M; Vallet S; Masquelier B; Flandre P; Calvez V;
Antivir Ther; 2012; 17(1):119-23. PubMed ID: 22267476
[TBL] [Abstract][Full Text] [Related]
10. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.
Bannister WP; Ruiz L; Cozzi-Lepri A; Mocroft A; Kirk O; Staszewski S; Loveday C; Karlsson A; Monforte Ad; Clotet B; Lundgren JD;
AIDS; 2008 Jan; 22(3):367-76. PubMed ID: 18195563
[TBL] [Abstract][Full Text] [Related]
11. Lack of effect of doxycycline on trough concentrations of protease inhibitors or non-nucleoside reverse transcriptase inhibitors in HIV-infected patients.
Abgrall S; Le Bel J; Lele N; Laouénan C; Eychenne N; Mentré F; Peytavin G; Bouchaud O;
HIV Clin Trials; 2013; 14(6):313-8. PubMed ID: 24334184
[TBL] [Abstract][Full Text] [Related]
12. Efavirenz Has the Highest Anti-Proliferative Effect of Non-Nucleoside Reverse Transcriptase Inhibitors against Pancreatic Cancer Cells.
Hecht M; Erber S; Harrer T; Klinker H; Roth T; Parsch H; Fiebig N; Fietkau R; Distel LV
PLoS One; 2015; 10(6):e0130277. PubMed ID: 26086472
[TBL] [Abstract][Full Text] [Related]
13. Non-nucleoside reverse transcriptase inhibitor outcomes among combination antiretroviral therapy-treated adults in Botswana.
Wester CW; Thomas AM; Bussmann H; Moyo S; Makhema JM; Gaolathe T; Novitsky V; Essex M; deGruttola V; Marlink RG
AIDS; 2010 Jan; 24 Suppl 1(Suppl 1):S27-36. PubMed ID: 20023437
[TBL] [Abstract][Full Text] [Related]
14. Etravirine for the treatment of HIV/AIDS.
Schrijvers R
Expert Opin Pharmacother; 2013 Jun; 14(8):1087-96. PubMed ID: 23560740
[TBL] [Abstract][Full Text] [Related]
15. Looking for an active conformation of the future HIV type-1 non-nucleoside reverse transcriptase inhibitors.
La Regina G; Coluccia A; Silvestri R
Antivir Chem Chemother; 2010 Aug; 20(6):213-37. PubMed ID: 20710063
[TBL] [Abstract][Full Text] [Related]
16. NNRTI plus PI combinations in the perspective of nucleoside-sparing or nucleoside-failing antiretroviral regimens.
Joly V; Descamps D; Yeni P
AIDS Rev; 2002; 4(3):128-39. PubMed ID: 12416447
[TBL] [Abstract][Full Text] [Related]
17. Clinical Pharmacodynamics, Pharmacokinetics, and Drug Interaction Profile of Doravirine.
Boyle A; Moss CE; Marzolini C; Khoo S
Clin Pharmacokinet; 2019 Dec; 58(12):1553-1565. PubMed ID: 31388941
[TBL] [Abstract][Full Text] [Related]
18. Emerging reverse transcriptase inhibitors for HIV-1 infection.
Rai MA; Pannek S; Fichtenbaum CJ
Expert Opin Emerg Drugs; 2018 Jun; 23(2):149-157. PubMed ID: 29737220
[TBL] [Abstract][Full Text] [Related]
19. [Etravirine drug interactions].
Pérez VE; Sánchez-Parra C; Serrano Villar S
Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():27-31. PubMed ID: 20116625
[TBL] [Abstract][Full Text] [Related]
20. [Data on rilpivirine in treatment-naïve patients. Lessons from ECHO, THRIVE and STaR].
Domingo P; Ribera E
Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():20-9. PubMed ID: 24252530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
